Dr. Daniel Petrylak on Early Trials for Urothelial Bladder Cancer Treatment

December 21, 2015
Daniel P. Petrylak, MD

Daniel P. Petrylak, MD, talks about taking the clinical trials examining MPDL3280A a step further for bladder cancer patients.

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and of Urology, professor and co-director, Signal Transduction Research Program, Yale Cancer Center, talks about taking the clinical trials examining MPDL3280A (anti—PD-L1) a step further.

Petrylak says patients with a high level of PD-L1 expression who are treated with the drug often have better responses than those without. Moreover, while MPDL3280A is still in its infancy, the treatment could be evolved into something that may be able to help a wider range of patients in the future, he adds.